GIST treatment decisions you can have confidence in
Oncology │ CRC │ BRAF V600E

BRAF V600E is now actionable in metastatic colorectal cancer

Specific results your oncologists can trust

Up to 15% of colorectal cancer cases have mutations in the BRAF gene (1) and of those mutations, V600E accounts for over 99% (2).

The therascreen BRAF V600E RGQ PCR Kit is an FDA-approved companion diagnostic (CDx) test to identify patients with cases of metastatic colorectal cancer (mCRC) that harbor the V600E mutation in the BRAF gene, and for whom treatment with BRAFTOVI (encorafenib) + cetuximab may be appropriate. The test uses DNA extracted from formalin-fixed, paraffin-embedded (FFPE) human colorectal cancer (CRC) tumor tissue.

Download flyer
Specific results your oncologists can trust

Start testing for BRAF V600E

Start testing for KRAS G12C
Find a laboratory offering testing using the therascreen BRAF V600E RGQ PCR Kit to start making informed colorectal cancer treatment decisions.
Find a lab
Contact an expert
Discover how BRAF V600E testing can help you and your patients.
Get in touch
Enabling precision healthcare for your patients
Our therascreen kits for solid tumor diagnostics allow you to access relevant genomic information for each patient and use it to make the best treatment decisions possible.
Browse our products
Enabling precision healthcare for your patients
A woman in protective goggles holding a tablet in a lab
Get the latest insights from oncology experts
Catch up with our solid tumor webinars wherever you are, at a time that works for you.
Go to hub

The therascreen BRAF V600E RGQ PCR Kit is intended for in vitro diagnostic use.

References

  1. Corcoran RB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2(3):227-35.
  2. COSMIC, the Catalogue of Somatic Mutations in Cancer. GRCh38/cosmic/v89/.